Alterity Therapeutics Reports Company Secretary Change
Ticker: PRNAF · Form: 6-K · Filed: Nov 19, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing-update
Related Tickers: ATHE
TL;DR
Alterity Therapeutics (ATHE) filed a 6-K for a Company Secretary change, incorporated into existing S-8/F-3 filings.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on November 19, 2024, to report a change in its Company Secretary. This filing is incorporated by reference into several of its existing SEC registration statements, including Form S-8 and Form F-3 filings.
Why It Matters
Changes in corporate officers like the Company Secretary can signal internal restructuring or administrative shifts within a company.
Risk Assessment
Risk Level: low — The filing is a routine administrative update and does not appear to contain material financial or operational news.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- Form S-8 (document) — Registration Statement
- Form F-3 (document) — Registration Statement
- Company Secretary (role) — Officer position
FAQ
What is the primary purpose of this Form 6-K filing?
The primary purpose of this Form 6-K filing is to report a change in the Company Secretary of Alterity Therapeutics Limited.
When was this Form 6-K filed?
This Form 6-K was filed on November 19, 2024.
Which SEC registration statements is this filing being incorporated into?
This Form 6-K is being incorporated by reference into Alterity Therapeutics Limited's Registration Statements on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076).
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office address is Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
What exhibit is submitted with this Form 6-K?
Exhibit 99.1, titled 'Change of Company Secretary- ATH', is submitted with this Form 6-K.
Filing Stats: 189 words · 1 min read · ~1 pages · Grade level 11.9 · Accepted 2024-11-19 08:00:32
Filing Documents
- ea0221761-6k_alterity.htm (6-K) — 14KB
- ea022176101ex99-1_alterity.htm (EX-99.1) — 9KB
- ex99-1_001.jpg (GRAPHIC) — 9KB
- 0001213900-24-099835.txt ( ) — 36KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Change of Company Secretary- ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: November 19, 2024 2